6FYP
X-RAY STRUCTURE OF CLK3-KD(GP-[275-632], NON-PHOS.)/CX-4945 AT 2.29A
Summary for 6FYP
| Entry DOI | 10.2210/pdb6fyp/pdb |
| Related | 6FYI 6FYK 6FYL 6FYO |
| Descriptor | Dual specificity protein kinase CLK3, 5-[(3-chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-carboxylic acid (3 entities in total) |
| Functional Keywords | splicing, transferase, kinase, tyrosine-protein kinase, serine/ threonine- protein kinase, nucleotide-binding |
| Biological source | Homo sapiens (Human) |
| Total number of polymer chains | 1 |
| Total formula weight | 42604.07 |
| Authors | Kallen, J. (deposition date: 2018-03-12, release date: 2018-07-18, Last modification date: 2024-01-17) |
| Primary citation | Kallen, J.,Bergsdorf, C.,Arnaud, B.,Bernhard, M.,Brichet, M.,Cobos-Correa, A.,Elhajouji, A.,Freuler, F.,Galimberti, I.,Guibourdenche, C.,Haenni, S.,Holzinger, S.,Hunziker, J.,Izaac, A.,Kaufmann, M.,Leder, L.,Martus, H.J.,von Matt, P.,Polyakov, V.,Roethlisberger, P.,Roma, G.,Stiefl, N.,Uteng, M.,Lerchner, A. X-ray Structures and Feasibility Assessment of CLK2 Inhibitors for Phelan-McDermid Syndrome. ChemMedChem, 13:1997-2007, 2018 Cited by PubMed Abstract: CLK2 inhibition has been proposed as a potential mechanism to improve autism and neuronal functions in Phelan-McDermid syndrome (PMDS). Herein, the discovery of a very potent indazole CLK inhibitor series and the CLK2 X-ray structure of the most potent analogue are reported. This new indazole series was identified through a biochemical CLK2 Caliper assay screen with 30k compounds selected by an in silico approach. Novel high-resolution X-ray structures of all CLKs, including the first CLK4 X-ray structure, bound to known CLK2 inhibitor tool compounds (e.g., TG003, CX-4945), are also shown and yield insight into inhibitor selectivity in the CLK family. The efficacy of the new CLK2 inhibitors from the indazole series was demonstrated in the mouse brain slice assay, and potential safety concerns were investigated. Genotoxicity findings in the human lymphocyte micronucleus test (MNT) assay are shown by using two structurally different CLK inhibitors to reveal a major concern for pan-CLK inhibition in PMDS. PubMed: 29985556DOI: 10.1002/cmdc.201800344 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.29 Å) |
Structure validation
Download full validation report
